Clinical Trials Logo

Adenocarcinoma of Lung clinical trials

View clinical trials related to Adenocarcinoma of Lung.

Filter by:
  • Withdrawn  
  • Page 1

NCT ID: NCT04870034 Withdrawn - Clinical trials for Malignant Solid Neoplasm

Binimetinib and Palbociclib Before Surgery for the Treatment of Operable KRAS-Positive Lung, Colorectal, or Pancreatic Cancer

Start date: January 15, 2024
Phase: Early Phase 1
Study type: Interventional

This early phase I trial studies the direct effects on cancer cells of the drugs binimetinib and palbociclib, in patients with KRAS-positive lung, colorectal, or pancreatic cancer that can be removed by surgery (operable). Binimetinib and palbociclib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving binimetinib and palbociclib may halt the growth of cancer cells and improve access of the immune system cells, a patient's own cells that fight infection and cancer, into the tumor.

NCT ID: NCT03361319 Withdrawn - Clinical trials for Adenocarcinoma of Lung

Combination Nab-paclitaxel (N-P) and Nintedanib or N-P and Placebo in Relapsed NSCLC Adenocarcinoma

N3
Start date: July 2020
Phase: Phase 1/Phase 2
Study type: Interventional

A PHASE I/II TRIAL OF COMBINATION NAB-PACLITAXEL AND NINTEDANIB OR NAB-PACLITAXEL AND PLACEBO IN RELAPSED NSCLC ADENOCARCINOMA

NCT ID: NCT02466568 Withdrawn - Lung Cancer Clinical Trials

Study of Nivolumab in Combination With GM.CD40L Vaccine in Adenocarcinoma of the Lung

Start date: July 2018
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this study is to find out what effects (good and bad) a tumor vaccine (GM.CD40L) used in combination with Nivolumab will have on participants and their cancer. Another purpose of the study is to find out the maximum tolerated dose of nivolumab in combination with GM.CD40L vaccine. Investigators also want to find out if the combination of GM.CD40L and nivolumab can boost the immune system of participants like you, and how their immune system reacts, both before and after the treatment.

NCT ID: NCT02341170 Withdrawn - Lung Cancer Clinical Trials

HS-PCI in Locally Advanced Adenocarcinoma of the Lung

HIPPO-S
Start date: January 2016
Phase: N/A
Study type: Interventional

The primary aim of this study is evaluate the impact of hippocampal-sparing prophylactic cranial irradiation (HS-PCI) on survival status in patients with nodal-positive (locally advanced) adenocarcinoma by comparing overall survival rates of patients undergoing HS-PCI to that of patients without this intervention. In addition, this study aims to investigate whether HS-PCI is detrimental on neurocognitive function and to evaluate its impact on the patient's quality of life.